{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:14:38Z","timestamp":1786976078277,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd008605.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000}}],"reference-count":94,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008605.pub3","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T08:03:11Z","timestamp":1480492991000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dopamine agonists for preventing ovarian hyperstimulation syndrome"],"prefix":"10.1002","author":[{"given":"Huilin","family":"Tang","sequence":"first","affiliation":[{"name":"Peking University Third Hospital; Department of Pharmacy; 49 North Garden Rd Haidian District Beijing China 100191"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Mourad","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre; Nijmegen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo-Di","family":"Zhai","sequence":"additional","affiliation":[{"name":"Peking University Third Hospital; Department of Pharmacy, Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University; 49 North Garden Rd Haidian District Beijing China 100191"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J","family":"Hart","sequence":"additional","affiliation":[{"name":"The University of Western Australia, King Edward Memorial Hospital and Fertility Specialists of Western Australia; School of Women's and Infants' Health; 374 Bagot Road Subiaco, Perth Western Australia Australia 6008"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD008605.pub3-BIB0001|cit1","first-page":"S103","article-title":"Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients","volume":"98","author":"Alhalabi","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub3-BIB0002|cit2","first-page":"P","article-title":"Quinagolide reduces OHSS in high risk ICSI patients","volume":"26","author":"Alhalabi","year":"2011","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0003|cit3","first-page":"i96","article-title":"The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients","volume":"21","author":"Alvarez","year":"2006","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.2007-0409","article-title":"Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction","volume":"92","author":"Alvarez","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1-2","key":"10.1002\/14651858.CD008605.pub3-BIB0005|cit5","first-page":"48","article-title":"Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial","volume":"60","author":"Amir","year":"2015","journal-title":"Journal of Reproductive Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.fertnstert.2011.07.325","article-title":"Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study","volume":"95","author":"Amir","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/09513590.2012.736554","article-title":"The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study","volume":"29","author":"Beltrame","year":"2013","journal-title":"Gynecological Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/humrep\/deq005","article-title":"The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial","volume":"25","author":"Busso","year":"2010","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","article-title":"Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study","volume":"17","author":"Carizza","year":"2008","journal-title":"Reproductive Biomedicine Online"},{"issue":"suppl 1","key":"10.1002\/14651858.CD008605.pub3-BIB0010|cit10","first-page":"i141","article-title":"Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg\/ml on the day of the hCG","volume":"23","author":"Carizza","year":"2008","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0011|cit11","first-page":"78","article-title":"Comparison of coasting with cabergoline administration for prevention of early severe OHSS","volume":"121","author":"Dalal","year":"2014","journal-title":"BJOG"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub3-BIB0012|cit12","first-page":"P","article-title":"Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF\/ICSI patients","volume":"29","author":"Fetisova","year":"2014","journal-title":"Human Reproduction"},{"issue":"7","key":"10.1002\/14651858.CD008605.pub3-BIB0013|cit13","first-page":"693","article-title":"Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction","volume":"20","author":"Ghahiri","year":"2015","journal-title":"Journal of Research in Medical Sciences"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub3-BIB0014|cit14","first-page":"4","article-title":"Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction","volume":"12","author":"Ghahiri","year":"2014","journal-title":"Iranian Journal of Reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0015|cit15","unstructured":"Jellad S Haj Hassine A Basly M Mrabet A Chibani M Rachdi R Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome Journal de Gyn\u00e9cologie, Obst\u00e9trique et Biologie de la Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejogrb.2013.07.010","article-title":"Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch","volume":"170","author":"Matorras","year":"2013","journal-title":"European Journal of Obstetrics and Gynecology and Reproductive Biology"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.EBX.0000413115.90725.a7","article-title":"Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?","volume":"2","author":"Salah","year":"2012","journal-title":"Evidence Based Women's Health Journal"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0018|cit18","first-page":"i60","article-title":"Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone","volume":"24","author":"Salah Edeen","year":"2009","journal-title":"Human Reproduction"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub3-BIB0019|cit19","first-page":"O","article-title":"Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome","volume":"24","author":"Shaltout","year":"2009","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejogrb.2012.08.008","article-title":"Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study","volume":"165","author":"Shaltout","year":"2012","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0021|cit21","first-page":"35","article-title":"Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients","volume":"3","author":"Sohrabvand","year":"2009","journal-title":"International Journal of Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10815-011-9708-4","article-title":"Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial","volume":"29","author":"Tehraninejad","year":"2012","journal-title":"Journal of Assisted Reproduction and Genetics"},{"issue":"10","key":"10.1002\/14651858.CD008605.pub3-BIB0023|cit23","first-page":"837","article-title":"Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study","volume":"11","author":"Torabizadeh","year":"2013","journal-title":"Iranian Journal of Reproductive Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0024|cit24","first-page":"51","article-title":"Comparison of coasting with cabergoline administration for prevention of early severe OHSS in ART cycles","volume":"6","author":"Aflatoonian","year":"2008","journal-title":"Iranian Journal of Reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0025|cit25","first-page":"70","article-title":"Cabergoline for prevention of ovarian hyperstimulation syndrome in high risk patients","volume":"8","author":"Agha Hosseini","year":"2010","journal-title":"Iranian Journal of reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0026|cit26","first-page":"3210","article-title":"Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study","volume":"22","author":"Alvarez","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1168.e1","DOI":"10.1016\/j.fertnstert.2009.05.021","article-title":"High dose cabergoline in management of ovarian hyperstimulation syndrome","volume":"92","author":"Ata","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13048-016-0237-8","article-title":"GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial","volume":"9","author":"Fouda","year":"2016","journal-title":"Journal of Ovarian Research"},{"issue":"184","key":"10.1002\/14651858.CD008605.pub3-BIB0029|cit29","first-page":"1","article-title":"Comparison of the effect of letrozole versus cabergoline for prevention of ovarian hyperstimulation syndrome (OHSS) in patients under ovulation induction treatments and IVF cycles","volume":"18","author":"Ghaebi","year":"2016","journal-title":"Iranian Journal of Obstetrics, Gynecology and Infertility"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/j.fertnstert.2011.07.994","article-title":"The effects of cabergoline on ovarian hyperstimulation syndrome (OHSS) and pregnancy outcomes on in vitro fertilization (IVF) patients","volume":"95","author":"Gualtieri","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.fertnstert.2010.07.705","article-title":"The effect of cabergoline on follicular microenvironment profile in patients with high risk of OHSS","volume":"94","author":"Guvendag","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"s1","key":"10.1002\/14651858.CD008605.pub3-BIB0032|cit32","first-page":"16","article-title":"Cabergoline does not appear to affect pregnancy rates in patients undergoing assisted reproduction","volume":"15","author":"Hatton","year":"2012","journal-title":"Human Fertility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0033|cit33","first-page":"207","article-title":"The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome","volume":"36","author":"Hosseini","year":"2011","journal-title":"Iranian Journal of Medical Science"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.fertnstert.2010.01.096","article-title":"Cabergoline and ganirelix therapy for early moderate to severe ovarian hyperstimulation syndrome (OHSS) results in faster recovery than in early untreated OHSS","volume":"93","author":"Khan","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/0974-1208.126293","article-title":"Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome","volume":"6","author":"Naredi","year":"2013","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1169.e15","DOI":"10.1016\/j.fertnstert.2009.05.062","article-title":"Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series","volume":"92","author":"Rollene","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.fertnstert.2009.07.1598","article-title":"Cabergoline and ganirelix treatment of ovarian hyperstimulation syndrome (OHSS) results in rapid clinical improvement","volume":"92","author":"Rollene","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"Supp1","key":"10.1002\/14651858.CD008605.pub3-BIB0038|cit38","first-page":"P","article-title":"Calcium dobesilate versus cabergoline for prevention of ovarian hyperstimulation syndrome","volume":"31","author":"Saad","year":"2016","journal-title":"Human Reproduction"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.rbmo.2013.03.002","article-title":"Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial","volume":"26","author":"Seow","year":"2013","journal-title":"Reproductive Biomedicine Online"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0974-1208.69342","article-title":"Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction","volume":"3","author":"Sherwal","year":"2010","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mefs.2010.10.004","article-title":"Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome","volume":"16","author":"Soliman","year":"2011","journal-title":"Middle East Fertility Society Journal"},{"issue":"8","key":"10.1002\/14651858.CD008605.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.fertnstert.2011.02.032","article-title":"Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome","volume":"95","author":"Spitzer","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3923\/rjog.2011.51.58","article-title":"Comparison of the clinical efficacy of two different cabergoline regimens on prevention of ovarian hyperstimulation syndrome (OHSS)","volume":"4","author":"Zargar","year":"2011","journal-title":"Research Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1472-6483(10)62518-7","article-title":"Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome","volume":"20","author":"Ahmadi","year":"2010","journal-title":"Reproductive Biomedicine Online"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub3-BIB0045|cit45","first-page":"6 Abstract O-13","article-title":"Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome","volume":"9","author":"Ahmadi","year":"2011","journal-title":"Iranian Journal of Reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0046|cit46","unstructured":"Cabergoline and Coasting to Prevent OHSS; Combining Cabergoline and Coasting in Gonadotropin Releasing Hormone(GnRH)Agonist Protocol in Intracytoplasmic Sperm Injection (ICSI) to Prevent Ovarian Hyperstimulation Syndrome (OHSS): a Randomized Clinical Trial Ongoing study"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0047|cit47","unstructured":"Comparative Study Between Cabergoline and Intravenous Calcium in the Prevention of Ovarian Hyperstimulation in Women with Polycystic Ovarian Disease Undergoing Intracytoplasmic Sperm Injection (ICSI) Ongoing study July 2013"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0048|cit48","unstructured":"Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers Ongoing study"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0049|cit49","unstructured":"Effect of Cabergoline on Endometrial Vascularity During Intracytoplasmic Sperm Injection Ongoing study December 2014"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0050|cit50","unstructured":"Diosmin versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (Infertility) Ongoing study May 2014"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0051|cit51","unstructured":"NCT01530490 Cabergoline and hydroxyethyl starch in ovarian hyperstimulation syndrome prevention clinicaltrials.gov\/ct2\/show\/NCT01530490"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001302","article-title":"Intravenous albumin for preventing severe ovarian hyperstimulation syndrome","author":"Aboulghar","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/humupd\/dmg018","article-title":"Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures","volume":"9","author":"Aboulghar","year":"2003","journal-title":"Human Reproduction Update"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1472-6483(10)60043-0","article-title":"Symposium: update on prediction and management of OHSS - prevention of OHSS","volume":"19","author":"Aboulghar","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub3-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001750.pub3","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","author":"Al-Inany","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/14647273.2013.833348","article-title":"Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis","volume":"16","author":"Baumgarten","year":"2013","journal-title":"Human Fertility (Cambridge, England)"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1472-6483(10)60044-2","article-title":"Symposium: update on prediction and management of OHSS: prevention of OHSS - dopamine agonists","volume":"19","author":"Busso","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"12","key":"10.1002\/14651858.CD008605.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1210\/jc.2015-3676","article-title":"Reducing the risk of OHSS by GnRH agonist triggering","volume":"100","author":"Casper","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1472-6483(10)60065-X","article-title":"Ovarian hyperstimulation, hyperprolactinaemia and LH gonadotroph adenoma","volume":"19","author":"Castelo-Branco","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0060|cit60","unstructured":"Cochrane Gynaecology and Fertility Group Module http:\/\/www.cochranelibrary.com\/review-group\/Gynaecology%20and%20Fertility%20Group\/"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1479-828X.2012.01448.x","article-title":"Treatment of infertility in polycystic ovary syndrome: a brief update","volume":"52","author":"Costello","year":"2012","journal-title":"Australian & New Zealand Journal of Obstetrics & Gynaecology"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002811","article-title":"Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome","author":"D'Angelo","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002806.pub2","article-title":"Embryo freezing for preventing ovarian hyperstimulation syndrome","author":"D'Angelo","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/humupd\/8.3.291","article-title":"A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients","volume":"18","author":"Delvigne","year":"2002","journal-title":"Human Reproduction Update"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1472-6483(10)60699-2","article-title":"IVF, IVM, natural cycle IVF, minimal stimulation IVF - time for a rethink","volume":"15","author":"Edwards","year":"2007","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14712598.3.2.263","article-title":"VEGF blocking therapy in the treatment of cancer","volume":"3","author":"Glade-Bender","year":"2003","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstetrical & Gynecological Survey"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0068|cit68","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"19093","DOI":"10.1038\/srep19093","article-title":"Pharmacologic interventions in preventing ovarian hyperstimulation syndrome: a systematic review and network meta-analysis","volume":"6","author":"Guo","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade","volume":"143","author":"G\u00f3mez","year":"2002","journal-title":"Endocrinology"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","article-title":"Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model","volume":"147","author":"G\u00f3mez","year":"2006","journal-title":"Endocrinology"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0072|cit72","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/09513590.2012.730578","article-title":"Cabergoline as treatment of ovarian hyperstimulation syndrome: a review","volume":"29","author":"Kalampokas","year":"2013","journal-title":"Gynecological Endocrinology"},{"issue":"9","key":"10.1002\/14651858.CD008605.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD008605.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3109\/09513590.2014.943716","article-title":"Dopamine agonists in prevention of ovarian hyperstimulation syndrome","volume":"30","author":"Kasum","year":"2014","journal-title":"Gynecological Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"719 e15-8","DOI":"10.1016\/j.fertnstert.2006.01.055","article-title":"Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas","volume":"86","author":"Knoepfelmacher","year":"2006","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0077|cit77","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.fertnstert.2013.11.005","article-title":"Cabergoline for the prevention of ovarian hyperstimulation syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Leitao","year":"2014","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejogrb.2005.01.009","article-title":"Cabergoline: a safe, easy, cheap, and effective drug for prevention\/treatment of ovarian hyperstimulation syndrome?","volume":"122","author":"Manno","year":"2005","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"b381","DOI":"10.1136\/bmj.b381","article-title":"Dopamine agonists and hyperprolactinaemia","volume":"338","author":"Martin","year":"2009","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD008605.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ogrm.2009.05.003","article-title":"Ovarian hyperstimulation syndrome: pathophysiology, prevention and management","volume":"19","author":"Prakash","year":"2009","journal-title":"Obstetrics, Gynaecology and Reproductive Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0002-9378(67)90137-8","article-title":"Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment","volume":"98","author":"Rabau","year":"1967","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0083|cit83","first-page":"11","article-title":"The management of ovarian hyperstimulation syndrome","volume":"Sept","author":"Royal College of Obstetricians and Gynaecologists (RCOG)","year":"2006","journal-title":"London (UK): Royal College of Obstetricians and Gynaecologists (RCOG)"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/humupd\/dmn008","article-title":"Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome","volume":"14","author":"Soares","year":"2008","journal-title":"Human Reproduction Update"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.fertnstert.2011.12.046","article-title":"Etiology of OHSS and use of dopamine agonists","volume":"97","author":"Soares","year":"2012","journal-title":"Fertility and Sterility"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub3-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008605.pub2","article-title":"Cabergoline for preventing ovarian hyperstimulation syndrome","author":"Tang","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008605.pub3-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006105.pub3","article-title":"Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome","author":"Tso","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008605.pub3-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009154.pub3","article-title":"Luteal phase support for assisted reproduction cycles","author":"Linden","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpobgyn.2009.02.006","article-title":"Ovarian hyperstimulation syndrome and complications of ART","volume":"23","author":"Vloeberghs","year":"2009","journal-title":"Best Practice & Research. Clinical Obstetrics & Gynaecology"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.rbmo.2012.08.001","article-title":"IVF versus ICSI for the fertilization of in-vitro matured human oocytes","volume":"25","author":"Walls","year":"2012","journal-title":"Reproductive Biomedicine Online"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/humrep\/deu248","article-title":"In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes","volume":"30","author":"Walls","year":"2015","journal-title":"Human Reproduction"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/humupd\/dmq006","article-title":"Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis","volume":"16","author":"Youssef","year":"2010","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD008605.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"New England Journal of Medicine"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008605.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008605.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:21:55Z","timestamp":1628533315000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008605.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecology and Fertility Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":94,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008605.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]}}}